Raymond James and Cantor both released bullish notes on uniQure (QURE) Tuesday following an update on the company's ...

UniQure stock doubled Tuesday after the company reached a testing agreement with the FDA for its Huntington's disease ...

Qure's AMT-130 shows promising results for Huntington’s disease. Learn why QURE stock faces commercialization challenges ...

Leerink raised the firm’s price target on uniQure (QURE) to $44 from $26 and keeps an Outperform rating on the shares. The firm notes the ...

Qure stock rallies 110% on reaching alignment with the FDA on key elements of an accelerated approval pathway for AMT-130 to ...

The company now says that, during a recent meeting with the FDA, the two parties agreed on some key elements for an ...

Crucially for the Netherlands-based biopharma company, the FDA has said that the composite Unified Huntington's Disease ...

Fintel reports that on December 10, 2024, Raymond James upgraded their outlook for uniQure N.V. (NasdaqGS:QURE) from ...

Verition Fund Management LLC lowered its position in uniQure (NASDAQ:QURE – Free Report) by 77.9% during the third quarter, ...

In a Type B meeting, the FDA signified that it will allow uniQure to use a natural history control, the composite Unified ...

The FDA will allow uniQure NV to seek accelerated approval for its Huntington’s disease gene therapy more than doubled the ...

Qure stock surges after FDA agrees on an accelerated approval pathway for its Huntington's disease treatment, AMT-130.